A Randomized Double Blind, Placebo Controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease over 18 Months

Grants and Contracts Details


Abstract The START study is a multicenter randomized, double-blind, placebo-controlled Phase 2 study designed to evaluate the efficacy, safety, and tolerability of two doses of CT1812 compared to placebo for approximately 18 months (72 weeks) in approximately 540 participants diagnosed with early Alzheimer’s disease (AD). This study is a public-private partnership with shared leadership responsibility across the Alzheimer’s Clinical Trial Consortium (ACTC) and Cognition Therapeutics, Inc.
Effective start/end date6/1/205/31/27


  • University of Southern California: $33,050.00


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.